Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
Running, not enrolling · Phase 3
Conditions studied: Colorectal Cancer
In brief
The primary purpose of this study is to evaluate XL092 + atezolizumab versus regorafenib in participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy.
Key facts
- Study ID
- NCT05425940
- Run by
- Exelixis
- People needed
- 901
- Starts
- 2022-09-07
- Expected to finish
- 2027-01-31
- Last updated by the study team
- 2026-07-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Exelixis Clinical Site #30 — Phoenix, Arizona, United States
- Exelixis Clinical Site #70 — Tucson, Arizona, United States
- Exelixis Clinical Site #9 — Duarte, California, United States
- Exelixis Clinical Site #55 — La Jolla, California, United States
- Exelixis Clinical Site #77 — Los Angeles, California, United States
- Exelixis Clinical Site #105 — Orange, California, United States
- Exelixis Clinical Site #80 — Santa Monica, California, United States
- Exelixis Clinical Site #5 — Santa Rosa, California, United States
- Exelixis Clinical Site #82 — Sylmar, California, United States
- Exelixis Clinical Site #58 — Torrance, California, United States
- Exelixis Clinical Site #81 — Whittier, California, United States
- Exelixis Clinical Site #125 — New Haven, Connecticut, United States
- Exelixis Clinical Site #16 — Miami Beach, Florida, United States
- Exelixis Clinical Site #60 — Orlando, Florida, United States
- Exelixis Clinical Site #4 — Marietta, Georgia, United States
- Exelixis Clinical Site #3 — Joliet, Illinois, United States
- Exelixis Clinical Site #102 — Indianapolis, Indiana, United States
- Exelixis Clinical Site #10 — Westwood, Kansas, United States
- Exelixis Clinical Site #47 — Lexington, Kentucky, United States
- Exelixis Clinical Site #7 — New Orleans, Louisiana, United States
- Exelixis Clinical Site #22 — St Louis, Missouri, United States
- Exelixis Clinical Site #8 — Billings, Montana, United States
- Exelixis Clinical Site #1 — Omaha, Nebraska, United States
- Exelixis Clinical Site #15 — Albuquerque, New Mexico, United States
- Exelixis Clinical Site #65 — Jonesboro, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.